Trial Profile
A Multicenter, Open-Label Phase 1 Study of DS-1205c in Combination With Osimertinib in Subjects With Metastatic or Unresectable EGFR-Mutant Non-Small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2024
Price :
$35
*
At a glance
- Drugs AB 329 (Primary) ; Osimertinib (Primary)
- Indications Adenocarcinoma; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Daiichi Sankyo Inc
- 21 Feb 2024 Last checked against ClinicalTrials.gov record.
- 09 Mar 2023 Results assessing to evaluate the safety and tolerability of DS-1205c, an oral AXL-receptor inhibitor, in combination with osimertinib in metastatic or unresectable EFGR-mutant non-small cell lung cancer (NSCLC) patients who developed disease progression during EGFR tyrosine kinase inhibitor (TKI) treatment published in the Investigational New Drugs
- 11 Nov 2021 Status changed from completed to discontinued based on a business decision by the Sponsor.